Drug Profile
TAK 828
Alternative Names: TAK-828Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Takeda
- Class
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease
Most Recent Events
- 10 May 2017 Discontinued - Phase-I for Crohn's disease (In volunteers) in USA (PO) based on results of preclinical toxicology and clinical teratogenicity studies (Takeda FY2016 Q4 results, May 2017)
- 01 Feb 2017 Takeda terminates a phase I trial in Healthy volunteers in USA (PO, Liquid) (NCT02817516)
- 01 Jul 2016 Takeda initiates enrolment in a phase I trial for Crohn's disease (In volunteers) in USA (NCT02817516)